Structural and functional cardiovascular changes were found in women 1 year after preeclamptic pregnancies [14], where the involvement of angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) and placental factors such as placental protein 13 (PP13) and the dysbalance thereof may be used to predict severity and long-term cardiovascular complications of preeclampsia [15,16]. This evidence concerns the gene LGALS13 and preeclampsia.